ArticleBritish journal of cancer2020

YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.

Lei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.